Literature DB >> 17440066

A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African Americans.

Christopher A Haiman1, V Wendy Setiawan, Lucy Y Xia, Loïc Le Marchand, Sue A Ingles, Giske Ursin, Michael F Press, Leslie Bernstein, Esther M John, Brian E Henderson.   

Abstract

Variation in the cytochrome P450 oxidoreductase (POR) gene, a key regulator of type II cytochrome P450 enzymes, may affect exposure to endogenous steroid hormones and breast cancer risk. We sequenced the POR locus and tested candidate polymorphisms G5G and A503V for association with breast cancer risk among women in the Multiethnic Cohort Study (1,615 cases and 1,962 controls). The single nucleotide polymorphism (SNP) A503V was common in all racial/ethnic populations (minor allele frequency, > or =0.05) but was not associated with risk. SNP G5G (A --> G nucleotide change), which lies in a suggestive exonic splicing enhancer motif in exon 1, was common only in African Americans (minor allele frequency, 0.21) and the homozygous state was modestly associated with increased breast risk among all cases [345 cases and 426 controls; odds ratio (OR), 1.64; 95% confidence interval (CI), 0.89-3.04; P = 0.12] and among cases with advanced disease (95 cases: OR, 3.08; 95% CI, 1.42-6.70; P = 0.005). In an attempt to replicate this association, we genotyped SNP G5G in additional African American case-control studies (747 cases and 468 controls). Nonsignificant positive associations were noted with the GG genotype class in all studies. In the pooled analysis (1,038 cases and 877 controls with genotype data), the association was statistically significant among all cases (OR, 1.58; 95% CI, 1.04-2.41; P = 0.03) and stronger in those with advanced disease (411 cases and 877 controls; OR, 2.60; 95% CI, 1.56-4.34; P = 0.0002). These data suggest that African Americans harbor an allele at the POR locus that may increase breast cancer risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440066     DOI: 10.1158/0008-5472.CAN-06-4801

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Mitochondrial DNA G10398A variant is not associated with breast cancer in African-American women.

Authors:  Veronica Wendy Setiawan; Li-Hao Chu; Esther M John; Yuan Chun Ding; Sue A Ingles; Leslie Bernstein; Michael F Press; Giske Ursin; Christopher A Haiman; Susan L Neuhausen
Journal:  Cancer Genet Cytogenet       Date:  2008-02

2.  Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations.

Authors:  Ningwu Huang; Vishal Agrawal; Kathleen M Giacomini; Walter L Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205

3.  FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation.

Authors:  Miriam S Udler; Kerstin B Meyer; Karen A Pooley; Eric Karlins; Jeffery P Struewing; Jinghui Zhang; David R Doody; Stewart MacArthur; Jonathan Tyrer; Paul D Pharoah; Robert Luben; Leslie Bernstein; Laurence N Kolonel; Brian E Henderson; Loic Le Marchand; Giske Ursin; Michael F Press; Paul Brennan; Suleeporn Sangrajrang; Valerie Gaborieau; Fabrice Odefrey; Chen-Yang Shen; Pei-Ei Wu; Hui-Chun Wang; Daehee Kang; Keun-Young Yoo; Dong-Young Noh; Sei-Hyun Ahn; Bruce A J Ponder; Christopher A Haiman; Kathleen E Malone; Alison M Dunning; Elaine A Ostrander; Douglas F Easton
Journal:  Hum Mol Genet       Date:  2009-02-17       Impact factor: 6.150

Review 4.  Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.

Authors:  Linda M Dong; John D Potter; Emily White; Cornelia M Ulrich; Lon R Cardon; Ulrike Peters
Journal:  JAMA       Date:  2008-05-28       Impact factor: 56.272

5.  Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.

Authors:  Delisha A Stewart; Jason H Winnike; Susan L McRitchie; Robert F Clark; Wimal W Pathmasiri; Susan J Sumner
Journal:  J Proteome Res       Date:  2016-08-03       Impact factor: 4.466

6.  iTRAQ proteomic identification of pVHL-dependent and -independent targets of Egln1 prolyl hydroxylase knockdown in renal carcinoma cells.

Authors:  Wendy D Haffey; Olga Mikhaylova; Jarek Meller; Ying Yi; Kenneth D Greis; Maria F Czyzyk-Krzeska
Journal:  Adv Enzyme Regul       Date:  2008-12-31

7.  Functional POR A503V is associated with the risk of bladder cancer in a Chinese population.

Authors:  Xue Xiao; Gaoxiang Ma; Shushu Li; Meilin Wang; Nian Liu; Lan Ma; Zhan Zhang; Haiyan Chu; Zhengdong Zhang; Shou-Lin Wang
Journal:  Sci Rep       Date:  2015-06-30       Impact factor: 4.379

Review 8.  Pharmacogenomics of human P450 oxidoreductase.

Authors:  Amit V Pandey; Patrick Sproll
Journal:  Front Pharmacol       Date:  2014-05-09       Impact factor: 5.810

9.  The POR rs10954732 polymorphism decreases susceptibility to hepatocellular carcinoma and hepsin as a prognostic biomarker correlated with immune infiltration based on proteomics.

Authors:  Yan Fang; Hongming Yang; Guiming Hu; Jiakun Lu; Jun Zhou; Na Gao; Yuhan Gu; Cunzhen Zhang; Jinhuan Qiu; Yuanyuan Guo; Yunfei Zhang; Qiang Wen; Hailing Qiao
Journal:  J Transl Med       Date:  2022-02-14       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.